Laryngeal cancer (LC) patients who meet the age and smoking criteria of the U.S. Preventive Services Task Force (USPSTF) for annual CT lung screening were analysed for pulmonary nodules (PN) detection and secondary lung cancer (SLC) diagnosis. This is a retrospective chart review of LC patients treated at Johns Hopkins Hospital from January 2010 to December 2017. The study population included patients who met USPSTF criteria by age and smoking history for annual chest screening and were followed for at least 3 consecutive years. A total of 998 LC patients' records were reviewed, of which 151 met the inclusion criteria. Inadequate follow-up period (37% of excluded cases) was the most common reason for exclusion, followed by not meeting USPSTF age criteria (27% excluded cases). In seventy-eight patients (n = 78, 52% of analysed patients) PN were reported. Nine individuals (6% of analysed patients) were diagnosed with SLC. Age over 70 (p = 0.003) was an independent predictor of malignancy. White race and smoking history over 40 pack-years were positively associated with a pulmonary nodule detection (p = 0.037 and p = 0.044, respectively). The incidence of PN and SLC in patients with LC is high. Many patients with laryngeal cancer meet the formal guidelines for USPSTF screening, and should be screened annually according to evidence-based medicine for the early detection of secondary lung cancers.
annual chest imaging with low dose CT and were followed for at least 3 consecutive years. All enrolled patients were treated and seen at Johns Hopkins Hospital, Baltimore, MD, USA between January 2010 and December 2017. The same database was used in the article Clinical practice patterns in laryngeal cancer and introduction of CT lung screening 10 .
The inclusion criteria were: being 55 to 77 years old at the time of the first recorded follow-up year, having consistent follow-up of at least 3 consecutive years in Johns Hopkins medical records system, smoking history of at least 30 pack-years in current smoker or those who quit within the past 15 years and not having synchronous lung cancer (or lugs metastases) or any other severe lung disease.
Between January 2010 and December 2017, 998 individuals with diagnosed LC (squamous cell carcinoma) were found. Eligible patients were identified in a 3-stage exclusion process as summarized in Fig. 1 . First, patients meeting the age criterion were selected; second, patients with follow-up shorter than 3 years were excluded; finally, patients with smoking history shorter than 30 pack-years or having pre-existing lung cancer were removed.
A detailed review of available medical history for each individual meeting inclusion criteria was performed. In Johns Hopkins Hospital, the electronic medical record (EMR) software storing patients' medical history is called EPIC ® (Verona, Wisconsin, United States). The study protocol involved for each enrolled patient: screening in EPIC all chest CT exams and other clinical notes to identify also pulmonary nodules detected outside Johns Hopkins Hospital or documented by outside providers. An additional EMR feature allows access to data of the largest outside imaging providers in Maryland, USA (American Radiology and Advanced Radiology). Figure 1 . Three stage exclusion protocol to identify index patients that meet USPSTF criteria for annual chest screening. Patients were excluded in three stages: (1) age, (2) inadequate follow-up, and finally (3) smoking history or synchronous lung cancer. Of 998 initial patients, 151 fully met study criteria and were included for further analysis. *Indicates the reason for exclusion. # For the purpose of the study, we defined synchronous tumors (synchronous lung cancer) as malignancies presenting within 6 months of diagnosis of the index tumors (here laryngeal cancer), and metachronous tumors (secondary lung cancer) as those presenting more than 6 months after diagnosis of the index tumor (here larygeal cancer).
Their database was also searched for any CT exams that might have not been visible in EPIC. For every CT found, we analyzed radiological reports in search for any detected pulmonary nodule larger than 4 mm. Size, number, change in size and location of detected nodules was extracted from radiological reports. Clinical and demographic characteristics such as sex, age, race, smoking pack-years, TNM-staging, tumor site were recorded.
Statistics. GraphPad Prism software (version 6.0, GraphPad Software, La Jolla, CA) was used to perform statistical analyses. The significance level for all calculations was p < 0.05.
Results
Patient characteristics. Following identification and exclusion protocols ( Fig. 1 ), 151 of 998 laryngeal cancer patients meeting inclusion criteria were analyzed. Demographic features of this population are found in Table 1 . The majority of the group were men (75.5%) and included patients with early, locally advanced, and advanced LC, fairly evenly divided between glottic (38.4%) and supraglottic (45.0%) cancer.
Pulmonary nodules in laryngeal cancer patients. During the study period, a total of 746 patient-years were analyzed and 514 CT reports found. In seventy-eight patients (52%) a total of 219 PN were reported ( Table 2 ). The majority of patients (52.5%) with positive findings had small pulmonary nodules with a maximum size of 4 to 5 mm, but the remainder had nodules significantly larger. Most frequently patients had 3 or more nodules detected over the screened period (48.7%), whereas only one nodule was found in 24 out of 78 patients (30.8%). The most common locations for PN were in the superior and inferior lobes (both 34.9%). In follow-up chest imaging, in most cases the detected nodules did not change in size (65.4%). Nevertheless, in 17 patients (21.8%) lung nodules increased in size on repeat imaging. In the analysed cohort, white race and smoking history over 40 pack-years were associated with greater risk of pulmonary nodule detection (p = 0.037 and p = 0.044, respectively). Sex, age, tumour site, T and N status were not significantly associated (Table 3 ). Because the design of the National Lung Screening Trial involved serial imaging over the course of three years, we were interested in how findings were detected in our cohort over the course of the three year inclusion criteria. In 49 cases (63%) pulmonary nodules were detected in the first CT imaging performed. Ten additional cases (13%) were identified by 2 nd CT, and ten more cases (13%) by the 3 rd CT. In 9 patients (11%), pulmonary nodules were detected in 4th or following chest CT (Fig. 2 ). Therefore, it appears that serial CT scan does improve the detection of pulmonary nodules over time, similar to findings in the National Lung Screening Trial 9 . Finally, we sought to identify factors associated with high-risk features of pulmonary nodules ( Fig. 3) 11, 12 . There was no correlation between the size of the nodule and smoking history in pack-years (p = 0.107, R 2 = 0.03385). However, there was a weak correlation between the number of detected nodules and smoking history in pack years (p = 0.0088, R 2 = 0.08677, respectively).
Secondary lung cancer in laryngeal cancer patients.
In the analysed group, SLC was diagnosed in 9 (6%) patients during the course of the study. Affected patients were predominantly men (78%) with mean age of 76 (range from 70 to 84) and mean smoking history of 72 pack-years (range from 30 to 150 pack years). There Johns Hopkins Hospital Cohort National Lung Screening Trial 9 Chi-square test ( www.nature.com/scientificreports www.nature.com/scientificreports/ was an average of five years between the primary diagnosis of LC and diagnosis of SLC (range from 1 to 12). Six out of nine (67%) patients who developed SLC were primarily diagnosed with supraglottic laryngeal cancer. The remaining 3 cases (33%) had a primary diagnosis of glottic cancer. Demographic and clinical data are presented in Table 4 .
In the analysed cohort, age over 70 years was the only factor significantly associated with greater risk of secondary lung cancer development (p = 0.003) ( Table 5) . Sex, race, smoking history, tumour site, T and N status were not significantly associated (p values: 1.00, 0.718, 0.272, 0.772, 1.00, 1.00, respectively).
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Discussion
Evidence-based medicine has established that a discrete group of high-risk patients benefits from annual lung cancer CT screening. The management of detected pulmonary nodules, appropriate risk stratification and follow-up strategies in this cohort is an intensive area of investigation in pulmonology, oncology, public health, radiology and many others after the introduction of USPSTF guidelines 8 . However, even though the results of the biggest clinical trial justifying the introduction of annual chest screening in smokers was published over 5 years ago, still little is known about the frequency of radiological findings or clinical benefits of the screening program in a large population of potential patients -those with previously diagnosed malignancy, who were excluded from the aforementioned study.
Knowing that smoking is a causative agent in many types of cancer, it seems justifiable to include those patients in annual screening problems as they often meet official USPTF criteria. In particular, it is widely known www.nature.com/scientificreports www.nature.com/scientificreports/ that head and neck cancer (HNSCC) patients are at significant risk of developing secondary lung malignancy. It has been reported that 5-19% of primary HNSCC patients develop SLC [3] [4] [5] [6] and this number is substantially higher than for smokers in general. The National Lung Screening Trial 9 included 53 454 smokers meeting 55-74 age criterion and 30 pack-years smoking history or having quitted within past 15 years. Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or carcinoma in situ in the 5 years prior to eligibility assessment was one of the major exclusion criterion. Pulmonary nodules were detected in 24.2% and malignant transformation observed in 4% of this studied population. By comparison, in our cohort we report a 52% rate of pulmonary nodules and a 6% rate of secondary lung cancer, rates that would seem to obviously justify annual screening when compared to the rates that merit annual CT screening in those without a prior diagnosis of malignancy. We acknowledge that it is possible that to some extent the rate of pulmonary nodules in our cohort depends on the differences in demographics between our study and NLST. Our cohort has a higher representation of non-white ethnicity patients (29.1% vs. 4.4% in NLST, Table 1 .), who proved to be significantly less frequently diagnosed with pulmonary nodules (Table 3) .
Our results are consistent with the previous report of Green et al. 7 , who reported that in a cohort of 400 HNSCC patients pulmonary nodules were present in 58% of patients and the lung malignancy rate equalled 6%. However, the aforementioned study included patients regardless of their age or smoking history and a Supraglottic  T1  N0  56  2010  2017  7   2  77  w  M  Supraglottic  T2  N0  100  2008  2012  4   3  71  o  M  Glottic  T2  N0  30  2003  2015  12   4  76  w  M  Glottic  T2  N0  150  2007  2015  8   5  83  w  M  Supraglottic  T3  N0  50  2012  2015  3   6  70  b  F  Supraglottic  T4  N0  50  2012  2014  2   7  72  w  F  Supraglottic  T2  N1  60  2005  2013  8   8  72  w  M  Supraglottic  T3  N2  45  2013  2014 www.nature.com/scientificreports www.nature.com/scientificreports/ considerable percentage of included patients had oropharyngeal cancer, where smoking is not as pronounced a risk factor as in laryngeal cancer. Therefore we believe that our study is unique and fills gap in the literature regarding prevalence of pulmonary nodules and secondary lung cancer in a carefully selected group of laryngeal cancer patients meeting USPSTF criteria for annual chest screening. The reported prevalence of PN and SLC in our study is higher than in the National Lung Screening Trial and surprisingly, white race proved to be significantly associated with greater risk of pulmonary nodule presence. To our knowledge, this finding has not been previously published in the available literature. The other factor positively associated with presence of PN, namely smoking history over 40 pack-years was expected and previously proved 13, 14 .
Lung cancer is the most common secondary malignancy in head and neck patients 15, 16 . The reported prevalence of secondary primary lung cancer in head and neck cancer patients ranges from 5-19% [3] [4] [5] [6] . In our study, the prevalence of secondary lung malignancy (6%) was quite low compared to the literature. However, unlike other studies we excluded all patients who were diagnosed with lung cancer within first 12 months following LC diagnosis and we had a homogenous population regarding primary tumour site. We show that the time between diagnosis of primary head and neck malignancy and secondary lung cancer varies between cases. The average of five years between diagnoses indicates that a substantial number of patients may develop lung cancer after their completed 5-year surveillance for laryngeal cancer, further evidence for the importance of continued screening for those patients that meet USPSTF criteria.
We admit there are some limitations to our study, the first being its retrospective character. Secondly, approximately 50% of patients meeting the age criterion were excluded based on the poor quality of follow-up record. Finally, another factor limiting our results is unreliable documentation of smoking history. To select patients definitely meeting USPSTF criteria for annual lung screening we were forced to exclude 172 patients based on their declared smoking history. In majority of cases, pack-years were not recorded in any form in their medical chart. As smoking history is one of the most important criterion in the introduced guidelines, accurate reporting of tobacco exposure in the standardized measure of pack-years should be a necessity in every day practice.
conclusion
The incidence of PN and SLC in patients with LC is high. Many patients with laryngeal cancer meet the formal guidelines for USPSTF screening, and should be screened annually according to evidence-based medicine for the early detection of secondary lung cancers.
